<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959996</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002307/MGH</org_study_id>
    <nct_id>NCT02959996</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain</brief_title>
  <official_title>Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to test whether the use of liposomal bupivacaine at the
      time of cesarean delivery may decrease post-operative pain scores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial. A total of 80 patients will be randomized 1:1 to
      intervention (liposomal bupivacaine) versus control (placebo solution).

      The planned intervention is the infiltration of liposomal bupivacaine (or control) at the
      time of fascial closure at a Pfannenstiel incision, after the delivery of the infant and
      repair of the hysterotomy. The procedure to instill the drug is as follows: Once the patient
      is in the operating room, neuraxial anesthesia will be administered per routine practice. A
      Pfannenstiel skin incision will be made. The usual cesarean delivery procedure will be
      performed at the discretion of the surgeon. Once the surgical team is about to begin fascial
      closure, the study drug will then be infiltrated by a member of the study team, with 50% of
      the study solution in subcutaneous space and 50% in the fascial plane, taking care to evenly
      spread the drug in the superior and inferior aspects of the incision. For the fascial
      infiltration, liposomal bupivacaine will be preferentially infiltrated laterally. The
      remainder of the cesarean delivery will proceed according to the usual fashion. At any point
      in the cesarean delivery, the surgeon may chose to administer or withhold ketorolac.

      Post-operative pain management will be: intrathecal morphine, scheduled ketorolac 30mg IV x
      24h followed by ibuprofen 600mg q6h x 24h, scheduled Tylenol 650mg q6h x 48h, and prn
      oxycodone 5-10mg q4h. This is the current pain management protocol for postoperative women
      after cesarean delivery. If Tylenol or NSAIDs are contraindicated, either due to the
      discretion of the clinical team or pre-existing patient contraindication, these will not be
      administered but are not a reason for study exclusion.

      The investigators plan to enroll 80 patients into this pilot study, 40 per group. This sample
      size is based on prior data among women who had a cesarean delivery at this institution, and
      were asked to report their pain scores with activity at 48- and 72- hours after operation.
      With this sample size, the investigators have 80% power to detect a 1.5 point difference in
      pain at 48 hours, and 90% power to detect a 1.5 point difference in pain at 72 hours, and
      account for any protocol violations or loss to follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">November 3, 2017</completion_date>
  <primary_completion_date type="Actual">September 25, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score With Activity</measure>
    <time_frame>at 48-hours post-operatively</time_frame>
    <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
2 patients in the liposomal bupivacaine group were discharged prior to 48 hour assessment, therefore denominator for this outcome is 37, not 39</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score With Activity</measure>
    <time_frame>at 72 -hours post-operatively</time_frame>
    <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
4 patients in the placebo group and 7 patients in the liposomal bupivacaine group were discharged prior to the 72 hour assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Use (in Morphine Equivalents)</measure>
    <time_frame>72-hours post-operatively</time_frame>
    <description>Total opioid use (in morphine equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Post-operative Pain Control</measure>
    <time_frame>48-hours post-operatively</time_frame>
    <description>PAIN OUT Tool, 0-10 scale, where 0 is not satisfied and 10 is satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Hospital Length of Stay</measure>
    <time_frame>0 to 96 hours postoperatively</time_frame>
    <description>Postoperative hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Wound Complication - Separation, Dehiscence, Infection</measure>
    <time_frame>14 days postoperatively</time_frame>
    <description>Wound complication - separation, dehiscence, infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Allergic Reaction Attributable to Local Anesthestic</measure>
    <time_frame>0-96 hours postoperatively</time_frame>
    <description>incisional rash, hives, anaphylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative Time of Cesarean Delivery</measure>
    <time_frame>Intraoperative time measurement, from skin incision to skin closure. Measured within 24h of admission.</time_frame>
    <description>Operative time of cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Pain Management at 6w Postpartum</measure>
    <time_frame>6 weeks postpartum</time_frame>
    <description>Phone follow up to ascertain satisfaction with pain control, Likert 5 point scale used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline will be infiltrated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal bupivacaine will be infiltrated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>liposomal bupivacaine injection in the Pfannenstiel incision</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo injection in the Pfannenstiel incision</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled cesarean delivery via Pfannenstiel incision;

          2. Planned neuraxial anesthetic with intrathecal morphine and fentanyl administration.

        Exclusion Criteria:

          1. Current or prior use of methadone, buprenorphine, or other opioids before cesarean
             delivery;

          2. Contraindication to neuraxial anesthetic;

          3. Allergy to local anesthetic;

          4. Planned general anesthetic.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H Barth, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <results_first_submitted>May 11, 2018</results_first_submitted>
  <results_first_submitted_qc>August 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2018</results_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Malavika Prabhu</investigator_full_name>
    <investigator_title>Clinical Fellow, Division of Maternal Fetal Medicine, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT02959996/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>40 patients enrolled in both groups, however 1 patient in the liposomal bupivacaine group was excluded after randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
        </group>
        <group group_id="P2">
          <title>Intervention</title>
          <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
        </group>
        <group group_id="B2">
          <title>Intervention</title>
          <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="3.7"/>
                    <measurement group_id="B2" value="35.6" spread="4.2"/>
                    <measurement group_id="B3" value="35.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, pre-pregnancy, kg/m2</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="6.4"/>
                    <measurement group_id="B2" value="26.2" spread="5.3"/>
                    <measurement group_id="B3" value="26.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score With Activity</title>
        <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
2 patients in the liposomal bupivacaine group were discharged prior to 48 hour assessment, therefore denominator for this outcome is 37, not 39</description>
        <time_frame>at 48-hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score With Activity</title>
          <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
2 patients in the liposomal bupivacaine group were discharged prior to 48 hour assessment, therefore denominator for this outcome is 37, not 39</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score With Activity</title>
        <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
4 patients in the placebo group and 7 patients in the liposomal bupivacaine group were discharged prior to the 72 hour assessment</description>
        <time_frame>at 72 -hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score With Activity</title>
          <description>Pain score with activity. PAIN OUT scale, which is a 0-10 scale, where 10 is more pain.
4 patients in the placebo group and 7 patients in the liposomal bupivacaine group were discharged prior to the 72 hour assessment</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Use (in Morphine Equivalents)</title>
        <description>Total opioid use (in morphine equivalents)</description>
        <time_frame>72-hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Use (in Morphine Equivalents)</title>
          <description>Total opioid use (in morphine equivalents)</description>
          <units>morphine milligram equivalents (MME)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="33.8" upper_limit="123.8"/>
                    <measurement group_id="O2" value="75" lower_limit="7.5" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Post-operative Pain Control</title>
        <description>PAIN OUT Tool, 0-10 scale, where 0 is not satisfied and 10 is satisfied</description>
        <time_frame>48-hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Post-operative Pain Control</title>
          <description>PAIN OUT Tool, 0-10 scale, where 0 is not satisfied and 10 is satisfied</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="9" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Hospital Length of Stay</title>
        <description>Postoperative hospital length of stay</description>
        <time_frame>0 to 96 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Hospital Length of Stay</title>
          <description>Postoperative hospital length of stay</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.5"/>
                    <measurement group_id="O2" value="3.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Wound Complication - Separation, Dehiscence, Infection</title>
        <description>Wound complication - separation, dehiscence, infection</description>
        <time_frame>14 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Wound Complication - Separation, Dehiscence, Infection</title>
          <description>Wound complication - separation, dehiscence, infection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Allergic Reaction Attributable to Local Anesthestic</title>
        <description>incisional rash, hives, anaphylaxis</description>
        <time_frame>0-96 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Allergic Reaction Attributable to Local Anesthestic</title>
          <description>incisional rash, hives, anaphylaxis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operative Time of Cesarean Delivery</title>
        <description>Operative time of cesarean delivery</description>
        <time_frame>Intraoperative time measurement, from skin incision to skin closure. Measured within 24h of admission.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Time of Cesarean Delivery</title>
          <description>Operative time of cesarean delivery</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Pain Management at 6w Postpartum</title>
        <description>Phone follow up to ascertain satisfaction with pain control, Likert 5 point scale used</description>
        <time_frame>6 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
          </group>
          <group group_id="O2">
            <title>Intervention</title>
            <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Pain Management at 6w Postpartum</title>
          <description>Phone follow up to ascertain satisfaction with pain control, Likert 5 point scale used</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Normal saline will be infiltrated
Placebo: placebo injection in the Pfannenstiel incision</description>
        </group>
        <group group_id="E2">
          <title>Intervention</title>
          <description>Liposomal bupivacaine will be infiltrated
Liposomal bupivacaine: liposomal bupivacaine injection in the Pfannenstiel incision</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Malavika Prabhu</name_or_title>
      <organization>Massachussetts General Hospital</organization>
      <phone>6177249028</phone>
      <email>mprabhu@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

